Use of cannabidiol in anxiety and anxiety-related disorders.

Skelley JW, Deas CM, Curren Z, Ennis J.
J Am Pharm Assoc (2003). 2019 Dec 19. pii: S1544-3191(19)30514-X. doi: 10.1016/j.japh.2019.11.008. [Epub ahead of print] Review.

PMID:31866386

Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects.

Breuer A, Haj CG, Fogaça MV, Gomes FV, Silva NR, Pedrazzi JF, Del Bel EA, Hallak JC, Crippa JA, Zuardi AW, Mechoulam R, Guimarães FS.
PLoS One. 2016 Jul 14;11(7):e0158779. doi: 10.1371/journal.pone.0158779. eCollection 2016. Erratum in: PLoS One. 2016;11(8):e0162087.

PMID:27416026
Free PMC Article

Cannabidiol as a Potential Treatment for Anxiety Disorders.

Blessing EM, Steenkamp MM, Manzanares J, Marmar CR.
Neurotherapeutics. 2015 Oct;12(4):825-36. doi: 10.1007/s13311-015-0387-1. Review.

PMID:26341731
Free PMC Article

Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.

Schier AR, Ribeiro NP, Silva AC, Hallak JE, Crippa JA, Nardi AE, Zuardi AW.
Braz J Psychiatry. 2012 Jun;34 Suppl 1:S104-10. Review. English, Portuguese.

PMID:22729452
Free Article

Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors.

Casarotto PC, Gomes FV, Resstel LB, Guimarães FS.
Behav Pharmacol. 2010 Jul;21(4):353-8.

PMID:20695034